Type 1 Diabetes Special Statutory Funding Program
Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)National Cancer Institute (NCI)
Abstract
The Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID) program is designed to assist translation to the clinic of novel therapeutic interventions for type 1 diabetes and its complications. These potential interventions can be either synthetic, natural product, or biologic. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials.
Requests are accepted twice yearly, on November 1 and April 1. The requests are reviewed by a panel of extramural experts within two to three months of receipt. Review criteria include strength of the scientific hypothesis, scientific novelty, and cost/benefit considerations afforded by the proposal.
T1D-RAID is not a grant mechanism. Approved requests to T1D-RAID gain access to the drug development contract resources of the National Cancer Institute's Developmental Therapeutics Program (NCI DTP). The output of the use of these resources is provided to the originating investigator, and may include GMP synthesized material, formulation research, pharmacological methods, or IND-directed toxicology, for support of an investigator-held IND application and clinical trials. T1D-RAID does not sponsor clinical trials; it sponsors the work needed to get ready to do clinical trials.
T1D-RAID Process and Procedures provides a detailed program description, request requirements, and submission deadlines.
T1D-RAID projects has information on the project that have previously been approved for support.
